Healthcare / Medical DevicesBrussels
$0.61
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-28.2M · quality 62.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
21/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$48M
P/E
N/A
•EV/EBITDA
N/A
•ROE
100.6%
↑Gross Margin
74.9%
↑Debt/Equity
-0.90
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
-34.2%
FCF CAGR
—
FCF margin
-19292.2%
FCF / Net income
0.46x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $105500.0 · net income $-44.7M · FCF $-20.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $105500.00 | $105500.00 | $712173.00 | $922687.00 | $370500.00 |
| Net Income | $-44.7M | $-44.7M | $-32.6M | $-30.8M | $-23.6M |
| EBITDA | $-41.1M | $-41.1M | $-29.4M | $-29.2M | $-22.3M |
| EPS | -1.22 | -1.22 | -1.22 | -1.35 | -1.30 |
| Gross Margin | 74.9% | 74.9% | 77.0% | 77.8% | 79.3% |
| Operating Margin | -17273.0% | -17273.0% | -4052.7% | -3044.9% | -6103.5% |
| Net Margin | -42325.7% | -42325.7% | -4572.4% | -3334.1% | -6373.8% |
| Balance Sheet | |||||
| Debt/Equity | -0.90 | -0.90 | -0.90 | -8.17 | -10.27 |
| Current Ratio | 0.20 | 0.20 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-20.4M | $-20.4M | $-29.8M | $-28.2M | $-23.9M |
| Returns | |||||
| ROE | 100.6% | 100.6% | 167.3% | 1428.7% | 3001.0% |
| Growth & Yield | |||||
| Revenue Growth | -85.2% | -85.2% | -22.8% | 149.0% | — |
| EPS Growth | 0.0% | 0.0% | 9.6% | -3.8% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-33.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.22 → -1.22
Residual
-33.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.